Giuseppe Lamberti
University of Bologna
PathologyLung cancerNeuroendocrine tumorsGeneral surgeryMedicine
What is this?
Publications 48
#1Giuseppe LambertiH-Index: 3
Last. Biagio Ricciuti (Harvard University)H-Index: 10
view all 5 authors...
DNA damage response and repair (DDR) genes play a central role in the life of actively replicating cells, cooperating to maintenance of genomic integrity. However, exogenous or endogenous factors, including deficiency in DDR genes, can cause different degrees of DNA damage that profoundly impacts the tumor immunogenicity and enhance antitumor immune response through neoantigen-dependent and neoantigen-independent mechanisms. Inhibition of DDRs is already an effective therapeutic strategy in diff...
#1Giuseppe LambertiH-Index: 3
#2Lisa ManuzziH-Index: 2
Last. Davide CampanaH-Index: 25
view all 4 authors...
#1G. Lamberti (Harvard University)H-Index: 1
#1Giuseppe Lamberti (Harvard University)H-Index: 3
Last. Andrew D. Cherniack (Harvard University)H-Index: 57
view all 11 authors...
INTRODUCTION: Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in non-small cell lung cancer (NSCLC), but factors associated with PD-L1 expression are not well understood. METHODS: Consecutive nonsquamous NSCLCs with successful PD-L1 assessment and targeted next-generation sequencing (NGS) were included in this retrospective study. Clinicopathological characteristics, gene mutations, and copy number cha...
#1Gonzalo Recondo (Harvard University)H-Index: 4
#2Robin Guo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Last. Tom Nguyen (Harvard University)H-Index: 5
view all 14 authors...
#1Giuseppe Lamberti (Harvard University)H-Index: 3
#2Sara PuscedduH-Index: 11
Last. Davide CampanaH-Index: 25
view all 7 authors...
#1Biagio Ricciuti (Harvard University)H-Index: 10
#2Kathryn Cecilia Arbour (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
Last. D. Venkatraman (Harvard University)
view all 20 authors...
#1Giovanni Vitale (UNIBO: University of Bologna)H-Index: 23
#2Giuseppe Lamberti (UNIBO: University of Bologna)H-Index: 3
Last. Francesco Gelsomino (UNIBO: University of Bologna)H-Index: 13
view all 8 authors...
Introduction: Monoclonal antibodies directed against programmed cell death-1 (anti-PD-1) and its ligand (anti-PD-L1) showed a significant efficacy among different immunogenic metastatic tumors such...
#1Giuseppe LambertiH-Index: 3
#2Maria Pia BrizziH-Index: 22
Last. Chiara Ciccarese (University of Verona)H-Index: 13
view all 15 authors...
There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PF...
#1Francesco GelsominoH-Index: 13
#2Marcello TiseoH-Index: 31
Last. Saverio CinieriH-Index: 32
view all 17 authors...
BACKGROUND: Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in relapsed SCLC. METHODS: In this multicentre prospective Phase 2 trial, patients with refractory or sensitive SCLC progressed to first-line platinum-based chemotherapy received nab-paclitaxel 100 mg/s...
#1Biagio Ricciuti (Harvard University)H-Index: 10
#2Gonzalo Recondo (Harvard University)H-Index: 4
Last. Lynette M. Sholl (Brigham and Women's Hospital)H-Index: 43
view all 13 authors...
PURPOSE: DNA damage response and repair (DDR) gene alterations are associated with increased tumor infiltrating lymphocytes, higher genomic instability, and higher tumor mutational burden (TMB) in cancer. Whether DDR alterations are associated with clinical outcomes to PD-(L)1 blockade in non-small cell lung cancer (NSCLC) is unknown. EXPERIMENTAL DESIGN: Tumors from patients treated with PD-(L)1 inhibitors were analyzed using targeted next-generation sequencing (NGS). Cancers were categorized b...